Clinical study on the treatment of influenza and upper respiratory tract infection (febrile virus attack lung syndrome) with Qingfeidayuan granules

Not Applicable

• Conditions: pper respiratory infection

• Registration Number: ITMCTR2100005151
• Lead Sponsor: Hubei Provincial Hospital of Traditional Chinese Medicine

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Meet the clinical diagnostic criteria for influenza or the diagnostic criteria for acute upper respiratory tract infection;
2. Comply with the standard of TCM heat-toxin attacking the lung syndrome;
3. Aged 18-70 years;
4. Fever duration <=48h; axillary temperature >=37.3?;
5. The informed consent process complies with the regulations, and the informed consent form is signed.

Exclusion Criteria

1. Severe or critical cases of influenza, or diagnosed as novel coronavirus pneumonia, pharyngeal conjunctival fever, herpetic angina, suppurative tonsillitis, etc.;
2. Complications of influenza such as sinusitis, otitis media and pneumonia have occurred;
3. The anti-influenza virus drugs included in the ''Influenza Diagnosis and Treatment Program (2020 Edition)'' have been used within 48 hours before the visit;
4. Systemically receiving steroid therapy or other immunosuppressive therapy;
5. Have a history of epilepsy or febrile convulsions;
6. Patients with severe malnutrition, rickets and serious primary diseases of the heart, brain, liver, kidney and hematopoietic system;
7. Pregnant or breastfeeding patients, allergic constitution, allergic to multiple drugs or allergic to known components of the research drug;
8. According to the judgment of the investigator, other diseases or conditions that reduce the possibility of enrollment or complicate enrollment, such as unstable living environment, inconvenient transportation, etc., are likely to cause loss to follow-up.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time for complete reduction of fever;

Secondary Outcome Measures

Name	Time	Method
Incidence of complications and weight loss;Rate of disappearance of individual symptoms and time required for disappearance or remission;TCM syndrome effect;Viral antigen negative conversion rate;Blood routine examination;